Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C.

Vergniol J, Boursier J, Coutzac C, Bertrais S, Foucher J, Angel C, Chermak F, Hubert IF, Merrouche W, Oberti F, de Lédinghen V, Calès P.

Hepatology. 2014 Jul;60(1):65-76. doi: 10.1002/hep.27069.

PMID:
24519328
2.

Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.

Poynard T, de Ledinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Le Naour G, Vaillant JC, Ratziu V, Charlotte F; Fibrosis-TAGS group..

J Hepatol. 2012 Mar;56(3):541-8. doi: 10.1016/j.jhep.2011.08.007.

PMID:
21889468
3.

Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C.

Loustaud-Ratti V, Alain S, Rousseau A, Hubert IF, Sauvage FL, Marquet P, Denis F, Lunel F, Calès P, Lefebvre A, Fauchais AL, Liozon E, Vidal E.

Hepatology. 2008 May;47(5):1453-61. doi: 10.1002/hep.22217.

PMID:
18435468
4.

Treatment of chronic hepatitis C with amantadine.

Hubert IF, Lunel F, Cadranel JF, Oberti F, Calès P.

Am J Gastroenterol. 1999 Aug;94(8):2316-7. No abstract available.

PMID:
10445578

Supplemental Content

Loading ...
Support Center